Tekmira Shares Soaring as First U.S. Diagnosis of Ebola Confirmed

Shares of Tekmira Pharmaceuticals, which makes the TKM-Ebola treatment, are soaring in Wednesday trading after the Centers for Disease Control and Prevention confirmed the first case of Ebola to be diagnosed in the United States. The patient, who traveled to Dallas, Texas from West Africa on September 20, has been isolated and local public health officials have begun identifying close contacts of the person for further monitoring. RBC Capital Markets analyst Michael Yee says the CDC may end up using Tekmira's drug to treat the U.S. patient or future patients, but in order to ultimately monetize anything, that treatment would have to lead to a U.S. 'stockpile order.'